AbCellera Biologics (ABCL) Total Liabilities (2020 - 2026)

AbCellera Biologics (ABCL) has 7 years of Total Liabilities data on file, last reported at $369.0 million in Q1 2026.

• Quarterly Total Liabilities rose 14.88% year-over-year to $369.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $369.0 million (up 14.88% YoY) and the FY2025 annual result came in at $390.0 million, up 28.11% from the prior year.
• Total Liabilities retreated to $369.0 million in Q1 2026, from $390.0 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $395.0 million in Q2 2025 to a low of $289.4 million in Q1 2023.
• A 5-year average of $340.8 million and a median of $333.2 million in 2024 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2022 — Total Liabilities jumped 124.49% — and 2023, when it retreated 24.78%.
• Tracing ABCL's Total Liabilities over 5 years: stood at $307.6 million in 2022, then advanced by 9.15% to $335.8 million in 2023, then decreased by 9.32% to $304.5 million in 2024, then grew by 28.11% to $390.0 million in 2025, then dropped by 5.39% to $369.0 million in 2026.
• The last three Total Liabilities figures came in at $369.0 million (Q1 2026), $390.0 million (Q4 2025), and $392.0 million (Q3 2025), per Business Quant data.